Published in Cancer Res on May 15, 1988
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci U S A (1989) 1.03
Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev (2008) 1.00
Differential permeability and quantitative MR imaging of a human lung carcinoma brain xenograft in the nude rat. Am J Pathol (1995) 0.92
Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1. J Neurol Neurosurg Psychiatry (1991) 0.85
Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG. Br J Cancer (1992) 0.80
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A (1987) 7.12
Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A (1992) 6.58
Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med (1989) 5.81
The clinical course of bone metastases from breast cancer. Br J Cancer (1987) 4.93
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
A tabulated summary of the FDG PET literature. J Nucl Med (2001) 4.37
Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med (1993) 4.28
Identification of an amplified, highly expressed gene in a human glioma. Science (1987) 4.21
Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res (2001) 3.45
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol (1999) 3.30
Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys (1997) 3.17
PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res (1997) 3.15
Deletion of p16 and p15 genes in brain tumors. Cancer Res (1994) 3.03
Coding of border ownership in monkey visual cortex. J Neurosci (2000) 2.92
FDG PET imaging in patients with pathologically verified dementia. J Nucl Med (2000) 2.70
Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol (1999) 2.69
Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res (1995) 2.67
Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey. Semin Diagn Pathol (1998) 2.65
Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol (1981) 2.65
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol (1998) 2.39
Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol (1998) 2.32
The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol (2004) 2.31
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol (2001) 2.31
Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A (1991) 2.27
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol (1999) 2.23
Mental stress--induced myocardial ischemia and cardiac events. JAMA (1996) 2.20
Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res (1983) 2.20
Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med (2001) 2.20
Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res (1991) 2.20
Pinhole collimation for ultra-high-resolution, small-field-of-view SPECT. Phys Med Biol (1994) 2.19
Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev (2008) 2.17
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res (1990) 2.15
Regulation of stroke volume during submaximal and maximal upright exercise in normal man. Circ Res (1986) 2.15
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer (2001) 2.14
Improved SPECT quantification using compensation for scattered photons. J Nucl Med (1984) 2.14
The skeletal metastatic complications of renal cell carcinoma. Int J Oncol (2001) 2.12
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol (1995) 2.09
Performance characteristics of a whole-body PET scanner. J Nucl Med (1994) 2.08
Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol (1986) 2.07
Staging non-small cell lung cancer with whole-body PET. Radiology (1999) 2.07
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev (2004) 2.05
Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol (1995) 2.05
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol (1991) 2.05
Successful therapy for trilateral retinoblastoma. Am J Ophthalmol (1992) 2.03
Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ (1995) 2.00
Sociodemographic and psychosocial factors in childhood as predictors of adult mortality. Am J Public Health (1995) 1.98
EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer (2001) 1.97
Acute pulmonary embolism: artificial neural network approach for diagnosis. Radiology (1993) 1.96
Predicting patient satisfaction from physicians' nonverbal communication skills. Med Care (1980) 1.95
Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res (1997) 1.89
Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res (1988) 1.89
Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. J Lab Clin Med (1977) 1.87
Bayesian reconstruction and use of anatomical a priori information for emission tomography. IEEE Trans Med Imaging (1996) 1.87
Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res (1988) 1.86
Sp-1 binds promoter elements regulated by the RB protein and Sp-1-mediated transcription is stimulated by RB coexpression. Proc Natl Acad Sci U S A (1993) 1.84
Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res (1993) 1.82
Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med (1997) 1.82
Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod Pathol (1998) 1.81
Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology (2008) 1.80
Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol (2008) 1.80
Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol (1998) 1.79
Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol (1998) 1.76
Pylorus-preserving pancreatoduodenectomy. A clinical and physiologic appraisal. Ann Surg (1986) 1.74
Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res (1999) 1.73
Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J (1997) 1.72
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer (2001) 1.70
Bone metastases and breast cancer. Cancer Treat Rev (1985) 1.67
Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res (2001) 1.67
Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol (1998) 1.64
Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis (2000) 1.63
A genetically tractable model of human glioma formation. Cancer Res (2001) 1.63
Infrequent p53 gene mutations in medulloblastomas. Cancer Res (1991) 1.62
Determinants of variable exercise performance among patients with severe left ventricular dysfunction. Am J Cardiol (1983) 1.62
[18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. AJNR Am J Neuroradiol (1993) 1.62
Effect of age on the response of the left ventricular ejection fraction to exercise. N Engl J Med (1980) 1.61
Prognostic value of radionuclide angiography in medically treated patients with coronary artery disease. A comparison with clinical and catheterization variables. Circulation (1990) 1.61
Cardiac phantom evaluation of simultaneously acquired dual-isotope rest thallium-201/stress technetium-99m SPECT images. J Nucl Med (1993) 1.61
Indium-LLL labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res (1976) 1.61
Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients? Clin Oncol (R Coll Radiol) (2010) 1.60
Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol (1997) 1.59
Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol (1998) 1.59
Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res (1990) 1.58
Alterations of the TP53 gene in human gliomas. Cancer Res (1994) 1.58
Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry (1996) 1.58